Megan Morisada1, Ellen C Moore1, Rachel Hodge1, Jay Friedman1, Harrison A Cash1, James W Hodge2, James B Mitchell3, Clint T Allen4. 1. Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States. 2. Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States. 3. Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States. 4. Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD, United States. Electronic address: clint.allen@nih.gov.
Abstract
OBJECTIVES: Determine if direct tumor cell cytotoxicity, antigen release, and susceptibility to T-lymphocyte killing following radiation treatment is dose-dependent. MATERIALS AND METHODS: Mouse oral cancer cells were engineered to express full-length ovalbumin as a model antigen. Tumor antigen release with uptake and cross presentation of antigen by antigen presenting cells with subsequent priming and expansion of antigen-specific T-lymphocytes following radiation was modeled in vitro and in vivo. T-lymphocyte mediated killing was measured following radiation treatment using a novel impedance-based cytotoxicity assay. RESULTS: Radiation treatment induced dose-dependent induction of executioner caspase activity and apoptosis in MOC1 cells. In vitro modeling of antigen release and T-lymphocyte priming demonstrated enhanced proliferation of OT-1 T-lymphocytes with 8Gy treatment of MOC1ova cells compared to 2Gy. This was validated in vivo following treatment of established MOC1ova tumors and adoptive transfer of antigen-specific T-lymphocytes. Using a novel impedance-based cytotoxicity assay, 8Gy enhanced tumor cell susceptibility to T-lymphocyte killing to a greater degree than 2Gy. CONCLUSION: In the context of using clinically-relevant doses of radiation treatment as an adjuvant for immunotherapy, 8Gy is superior to 2Gy for induction of antigen-specific immune responses and enhancing tumor cell susceptibility to T-lymphocyte killing. These findings have significant implications for the design of trials combining radiation and immunotherapy. Published by Elsevier Ltd.
OBJECTIVES: Determine if direct tumor cell cytotoxicity, antigen release, and susceptibility to T-lymphocyte killing following radiation treatment is dose-dependent. MATERIALS AND METHODS:Mouseoral cancer cells were engineered to express full-length ovalbumin as a model antigen. Tumor antigen release with uptake and cross presentation of antigen by antigen presenting cells with subsequent priming and expansion of antigen-specific T-lymphocytes following radiation was modeled in vitro and in vivo. T-lymphocyte mediated killing was measured following radiation treatment using a novel impedance-based cytotoxicity assay. RESULTS: Radiation treatment induced dose-dependent induction of executioner caspase activity and apoptosis in MOC1 cells. In vitro modeling of antigen release and T-lymphocyte priming demonstrated enhanced proliferation of OT-1 T-lymphocytes with 8Gy treatment of MOC1ova cells compared to 2Gy. This was validated in vivo following treatment of established MOC1ova tumors and adoptive transfer of antigen-specific T-lymphocytes. Using a novel impedance-based cytotoxicity assay, 8Gy enhanced tumor cell susceptibility to T-lymphocyte killing to a greater degree than 2Gy. CONCLUSION: In the context of using clinically-relevant doses of radiation treatment as an adjuvant for immunotherapy, 8Gy is superior to 2Gy for induction of antigen-specific immune responses and enhancing tumor cell susceptibility to T-lymphocyte killing. These findings have significant implications for the design of trials combining radiation and immunotherapy. Published by Elsevier Ltd.
Authors: Stephan R Scheffer; Heike Nave; Firouzeh Korangy; Karola Schlote; Reinhard Pabst; Elizabeth M Jaffee; Michael P Manns; Tim F Greten Journal: Int J Cancer Date: 2003-01-10 Impact factor: 7.396
Authors: Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord Journal: J Immunol Date: 2005-06-15 Impact factor: 5.422
Authors: Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531
Authors: Michaela K Keck; Zhixiang Zuo; Arun Khattri; Thomas P Stricker; Christopher D Brown; Matin Imanguli; Damian Rieke; Katharina Endhardt; Petra Fang; Johannes Brägelmann; Rebecca DeBoer; Mohamed El-Dinali; Serdal Aktolga; Zhengdeng Lei; Patrick Tan; Steve G Rozen; Ravi Salgia; Ralph R Weichselbaum; Mark W Lingen; Michael D Story; K Kian Ang; Ezra E W Cohen; Kevin P White; Everett E Vokes; Tanguy Y Seiwert Journal: Clin Cancer Res Date: 2014-12-09 Impact factor: 12.531
Authors: Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber Journal: J Exp Med Date: 2011-09-19 Impact factor: 14.307
Authors: Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes Journal: J Exp Med Date: 2006-04-24 Impact factor: 14.307
Authors: Sofia R Gameiro; Jack P Higgins; Matthew R Dreher; David L Woods; Goutham Reddy; Bradford J Wood; Chandan Guha; James W Hodge Journal: PLoS One Date: 2013-07-24 Impact factor: 3.240
Authors: Roy Xiao; Clint T Allen; Linda Tran; Priya Patel; So-Jin Park; Zhong Chen; Carter Van Waes; Nicole C Schmitt Journal: Oncoimmunology Date: 2018-08-01 Impact factor: 8.110
Authors: Jay Friedman; Ellen C Moore; Paul Zolkind; Yvette Robbins; Paul E Clavijo; Lilian Sun; Sarah Greene; Megan V Morisada; Wojciech K Mydlarz; Nicole Schmitt; James W Hodge; Hans Schreiber; Carter Van Waes; Ravindra Uppaluri; Clint Allen Journal: Clin Cancer Res Date: 2019-10-23 Impact factor: 12.531
Authors: Ayman J Oweida; Laurel Darragh; Andy Phan; David Binder; Shilpa Bhatia; Adam Mueller; Benjamin Van Court; Dallin Milner; David Raben; Richard Woessner; Lynn Heasley; Raphael Nemenoff; Eric Clambey; Sana D Karam Journal: J Natl Cancer Inst Date: 2019-12-01 Impact factor: 13.506
Authors: Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal Journal: Front Oncol Date: 2021-04-21 Impact factor: 6.244
Authors: Ellen C Moore; Lillian Sun; Paul E Clavijo; Jay Friedman; Joe B Harford; Anthony D Saleh; Carter Van Waes; Esther H Chang; Clint T Allen Journal: Oncoimmunology Date: 2018-05-07 Impact factor: 8.110